Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia

Koenraad Van Doorslaer, Laura L. Reimers, Yevgeniy Y. Studentsov, Mark H. Einstein, Robert D. Burk

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. Experimental design: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. Results: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p = 0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. Conclusions: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored.

Original languageEnglish (US)
Pages (from-to)208-212
Number of pages5
JournalGynecologic Oncology
Volume116
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Uterine Cervical Dysplasia
Vaccines
Immunoglobulin G
Therapeutics
Carcinoma in Situ
Cytotoxic T-Lymphocytes
Therapeutic Uses
Heat-Shock Proteins
Oncogenes
Uterine Cervical Neoplasms
Immunotherapy
Vaccination
Proteins
B-Lymphocytes
Research Design
Clinical Trials
Infection
Serum
Neoplasms

Keywords

  • Cervical carcinoma
  • HPV
  • HspE7
  • IgG
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. / Van Doorslaer, Koenraad; Reimers, Laura L.; Studentsov, Yevgeniy Y.; Einstein, Mark H.; Burk, Robert D.

In: Gynecologic Oncology, Vol. 116, No. 2, 02.2010, p. 208-212.

Research output: Contribution to journalArticle

Van Doorslaer, Koenraad ; Reimers, Laura L. ; Studentsov, Yevgeniy Y. ; Einstein, Mark H. ; Burk, Robert D. / Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. In: Gynecologic Oncology. 2010 ; Vol. 116, No. 2. pp. 208-212.
@article{70880160ce3449b9994180c60c129e94,
title = "Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia",
abstract = "Purpose: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. Experimental design: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. Results: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p = 0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. Conclusions: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored.",
keywords = "Cervical carcinoma, HPV, HspE7, IgG, Therapeutic vaccine",
author = "{Van Doorslaer}, Koenraad and Reimers, {Laura L.} and Studentsov, {Yevgeniy Y.} and Einstein, {Mark H.} and Burk, {Robert D.}",
year = "2010",
month = "2",
doi = "10.1016/j.ygyno.2009.05.044",
language = "English (US)",
volume = "116",
pages = "208--212",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia

AU - Van Doorslaer, Koenraad

AU - Reimers, Laura L.

AU - Studentsov, Yevgeniy Y.

AU - Einstein, Mark H.

AU - Burk, Robert D.

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. Experimental design: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. Results: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p = 0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. Conclusions: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored.

AB - Purpose: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. Experimental design: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. Results: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p = 0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. Conclusions: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored.

KW - Cervical carcinoma

KW - HPV

KW - HspE7

KW - IgG

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=73949130821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949130821&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.05.044

DO - 10.1016/j.ygyno.2009.05.044

M3 - Article

VL - 116

SP - 208

EP - 212

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -